mmpR5 Family assigned · medium auto-curated

H37Rv Rv0678 · MTBC0 mtbc0_000717 · 165 aa · 783076–783573 MTBC0 (+) · RefSeq NP_215192.1

Conflicting signals on this page. Two layers of this record disagree. Neither has been suppressed; what follows says what is known and what the disagreement means.
  • Le TSS mesure tombe du mauvais cote (aval) du candidat start reannote que cette meme ligne propose, ce qui rend new_utr_bp negatif : anomalie arithmetique interne heritee de la table source (Cortes 2013 Table S3), sous investigation en P49 (couche tss, requalifiee par phase233 le 2026-09-15 mais pas garantie exacte sur toutes les lignes). Score bass negatif sur les 16 fiches concernees, coherent avec un appel TSS de faible confiance. Non reparee ici (P46.11), renvoyee a P49. (tss utr negative, 2026-09-22)

Genomic neighbourhood (genome browser)

Open in full genome browser →

This gene (outlined) in its genomic context; arrows are neighbouring genes coloured by verdict. Click any gene to navigate. Pan and zoom in the full browser.

Annotation: from legacy to revised

Legacy (H37Rv / Mycobrowser)hypothetical protein
MTBC0 PGAP re-annotationsiderophore transport transcriptional regulator MmpR5
Revised (this work)Siderophore transport transcriptional regulator MmpR5. Pfam: HTH_MmpR5 (PF27059.1).
Functional category (TubercuList)conserved hypotheticals

Curation note: P16.23 (phase135, 2026-08-17): couche tss ajoutee (leaderless=False). P49.1 (phase233, 2026-09-15): couche tss re-clee (leaderless=True).

Auto-curated: this verdict and function were generated by rules from PGAP + Pfam + Foldseek and have not been hand-reviewed.

In the literature (TB corpus sweep) 57 publications

Found under: H37Rv (57).

57 TB publications mention this gene. 57 publication(s) mention this gene (title/abstract), verified against the text. The atlas states the function; these are the primary sources that discuss it.

5 of 57: the most recently indexed records of the curated sweep at its date, not necessarily the most recent papers on this gene — the exhaustive list below is later and broader and may hold newer ones.
PublicationDate
Comparative in vitro antimicrobial susceptibility profiles of clofazimine and pyrifazimine against clinical isolates of Mycobacterium tuberculosis in southwest China. doi:10.1128/spectrum.02664-25 2026
A Case of Transmission of Bedaquiline- and Linezolid-Resistant Tuberculosis. doi:10.3390/ijms27114912 2026
Phenotypic drug susceptibility testing and genotypic characterization of Bedaquiline resistance in drug resistant Mycobacteriumtuberculosis. doi:10.1016/j.ijmmb.2026.101163 2026
Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing. doi:10.1038/s41467-026-73551-w 2026
Bedaquiline resistance-associated genetic mutations and minimum inhibitory concentrations in drug-resistant tuberculosis clinical isolates from Limpopo province, South Africa. doi:10.3389/fmicb.2026.1803115 2026
150 records returned by the alias sweep (a separate sweep from the 57 above; both are shown, neither is exhaustive)

Searched as: Rv0678, mmpR5, Mb0697, MMAR_1007 — each in conjunction with a mycobacterial context term. Swept 2026-09-07.

PublicationJournalYear
No phenotypic resistance observed for most group-3 and -4 variants in Mycobacterium tuberculosis genes related to bedaquiline, clofazimine, delamanid, and pretomanid in a Central and West African context. doi:10.1128/spectrum.02005-26 Microbiol Spectr 2026
Rapid detection of treatment-emergent resistance to bedaquiline and pretomanid in Mycobacterium tuberculosis using TM4::GeNL reporter mycobacteriophages. doi:10.1128/spectrum.03900-25 Microbiol Spectr 2026
In vitro pharmacokinetics and pharmacodynamics of the diarylquinoline TBAJ-587 and its metabolites against Mycobacterium tuberculosis. doi:10.3389/fmicb.2026.1828998 Front Microbiol 2026
Comparative in vitro antimicrobial susceptibility profiles of clofazimine and pyrifazimine against clinical isolates of Mycobacterium tuberculosis in southwest China. doi:10.1128/spectrum.02664-25 Microbiol Spectr 2026
A Case of Transmission of Bedaquiline- and Linezolid-Resistant Tuberculosis. doi:10.3390/ijms27114912 Int J Mol Sci 2026
Phenotypic drug susceptibility testing and genotypic characterization of Bedaquiline resistance in drug resistant Mycobacteriumtuberculosis. doi:10.1016/j.ijmmb.2026.101163 Indian J Med Microbiol 2026
Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing. doi:10.1038/s41467-026-73551-w Nat Commun 2026
Primary bedaquiline-resistant tuberculosis in an Afghan migrant to Switzerland: Diagnostic and treatment challenges in a high-resource setting. doi:10.1016/j.ijid.2026.108870 Int J Infect Dis 2026
Bedaquiline resistance-associated genetic mutations and minimum inhibitory concentrations in drug-resistant tuberculosis clinical isolates from Limpopo province, South Africa. doi:10.3389/fmicb.2026.1803115 Front Microbiol 2026
Global mapping of bedaquiline-resistant Mycobacterium tuberculosis: a systematic review. doi:10.1186/s12879-026-13171-3 BMC Infect Dis 2026
Bedaquiline Resistance in Drug-Resistant Tuberculosis in South Africa: A Systematic Review and Meta-Analysis of Emerging Trends. doi:10.3390/antibiotics15040385 Antibiotics (Basel) 2026
Second-Generation Anti-Tubercular Squaramides Targeting Complex V of the Respiratory Chain of Mycobacterium tuberculosis Displaying Enhanced Metabolic Stability. doi:10.1021/acs.jmedchem.5c03274 J Med Chem 2026
Emergence of Rv0678 (mmpR5) mutations mediating resistance to bedaquiline and clofazimine in a liver transplant recipient with rifampicin-susceptible tuberculosis: A case report. doi:10.1016/j.ijid.2026.108587 names it Int J Infect Dis 2026
Menaquinone depletion resensitises bedaquiline-resistant tuberculosis. doi:10.64898/2026.02.10.702511 bioRxiv 2026
Bedaquiline resistance in patients with Xpert MTB/RIF Ultra-tested rifampicin-resistant tuberculosis in the Western Cape, South Africa: a prospective study. doi:10.1016/j.lanmic.2025.101293 Lancet Microbe 2026
Bedaquiline Resistance: A Looming Global Threat in Tuberculosis Management. doi:10.1007/s00284-025-04655-7 Curr Microbiol 2025
Whole genome sequencing-based detection of extensively drug-resistant tuberculosis from Ethiopia. doi:10.1038/s43856-025-01271-1 Commun Med (Lond) 2025
Examination of Genetic Mutations of Clofazimine Resistance in Drug-Resistant Mycobacterium TB Isolates. doi:10.1007/s00284-025-04582-7 Curr Microbiol 2025
Low-level BTZ-043 resistance in Mycobacterium tuberculosis and cross-resistance to bedaquiline and clofazimine. doi:10.5588/ijtldopen.25.0301 IJTLD Open 2025
Structural and functional analysis of the Mycobacterium tuberculosis MmpS5L5 efflux pump presages increased bedaquiline resistance. doi:10.1073/pnas.2516660122 Proc Natl Acad Sci U S A 2025
In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis. doi:10.1128/aac.01113-25 Antimicrob Agents Chemother 2025
Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare. doi:10.1093/jac/dkaf321 J Antimicrob Chemother 2025
Effect of Bdq-Containing Regimen and Molecular Detection of Bdq Resistance among Pre-XDR-TB Patients with Unfavorable Outcomes. doi:10.2147/IJGM.S538660 Int J Gen Med 2025
Investigation of delamanid, bedaquiline, and linezolid resistance rates and related gene mutations in multidrug-resistant Mycobacterium tuberculosis in regional tuberculosis reference laboratories of Iran. doi:10.1186/s12866-025-04213-y BMC Microbiol 2025
Quality control and considering systematic MIC shifts are key when evaluating the role of mmpR5 (Rv0678) frameshifts in bedaquiline resistance. doi:10.1128/aac.00266-25 names it Antimicrob Agents Chemother 2025
Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing. doi:10.1128/aac.00356-25 Antimicrob Agents Chemother 2025
Structural and functional analysis of the Mycobacterium tuberculosis MmpS5L5 efflux pump presages a pathway to increased bedaquiline resistance. doi:10.1101/2025.06.24.661325 bioRxiv 2025
Linking genetic and phenotypic bedaquiline resistance in Mycobacterium tuberculosis strains from Georgia. doi:10.1371/journal.pone.0326794 PLoS One 2025
An improved catalogue for whole-genome sequencing prediction of bedaquiline resistance in Mycobacterium tuberculosis using a reproducible algorithmic approach. doi:10.1099/mgen.0.001429 Microb Genom 2025
[Bedaquiline susceptibility and molecular mutation characteristics of Mycobacterium tuberculosis in Guizhou Province]. doi:10.3760/cma.j.cn112147-20250123-00050 Zhonghua Jie He He Hu Xi Za Zhi 2025
The mutant selection window of moxifloxacin and bedaquiline resistant Mycobacterium tuberculosis. doi:10.1016/j.jinf.2025.106523 J Infect 2025
Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis. doi:10.1186/s12879-025-11067-2 BMC Infect Dis 2025
Whole-genome sequencing analysis to identify antimicrobial resistance regions and virulence factors in Mycobacterium tuberculosis isolates from the Amhara Region, Ethiopia. doi:10.1038/s41598-025-01241-6 Sci Rep 2025
Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis. doi:10.1128/aac.00019-25 Antimicrob Agents Chemother 2025
Mycobactin and clofazimine activity are negatively correlated in mycobacteria. doi:10.3389/fmicb.2025.1539139 Front Microbiol 2025
Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity. doi:10.1073/pnas.2426827122 Proc Natl Acad Sci U S A 2025
Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from Armenia. doi:10.1128/aac.01839-24 Antimicrob Agents Chemother 2025
Unpacking bedaquiline hetero-resistance: the importance of intermediate profiles for phenotypic drug-susceptibility testing. doi:10.1101/2025.03.09.642295 bioRxiv 2025
High Prevalence of atpE Mutations in Bedaquiline-Resistant Mycobacterium tuberculosis Isolates, Russia. doi:10.3201/eid3103.241488 Emerg Infect Dis 2025
Investigation of bedaquiline heteroresistance among Mycobacterium tuberculosis isolates from Pakistan. doi:10.1128/spectrum.02181-24 Microbiol Spectr 2025
In vitro monitoring of drug resistance emergence during stepwise induction of bedaquiline and clofazimine, alone and in combination: a phenotypic and genotypic analysis. doi:10.1093/jac/dkae405 J Antimicrob Chemother 2025
Mice infected with M. tuberculosis with Rv0678 mutations still benefit from bedaquiline treatment. doi:10.5588/ijtldopen.23.0527 names it IJTLD Open 2024
Analysis of genetic characteristics associated with reduced bedaquiline susceptibility in multidrug-resistant Mycobacterium tuberculosis. doi:10.1016/j.tube.2024.102572 Tuberculosis (Edinb) 2024
Frameshift mutations in the mmpR5 gene can have a bedaquiline-susceptible phenotype by retaining a protein structure and function similar to wild-type Mycobacterium tuberculosis. doi:10.1128/aac.00854-24 names it Antimicrob Agents Chemother 2024
A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis. doi:10.1002/jcla.25091 J Clin Lab Anal 2024
Phenotypic and genotypic analysis of drug resistance in M. tuberculosis isolates in Gansu, China. doi:10.1371/journal.pone.0311042 PLoS One 2024
Mutations in Rv0678, Rv2535c, and Rv1979c Confer Resistance to Bedaquiline in Clinical Isolates of Mycobacterium Tuberculosis. doi:10.2174/0118761429314641240815080447 names it Curr Mol Pharmacol 2024
Cartridge-based sequencing for bedaquiline resistance detection from sputum. doi:10.5588/ijtldopen.24.0124 IJTLD Open 2024
Clinical application of whole-genome sequencing in the management of extensively drug-resistant tuberculosis: a case report. doi:10.1186/s12941-024-00737-9 Ann Clin Microbiol Antimicrob 2024
Delamanid and bedaquiline resistance patterns in Mycobacterium tuberculosis in Iran: A cross-sectional analysis. doi:10.1016/j.nmni.2024.101437 New Microbes New Infect 2024
MmpR5 protein truncation and bedaquiline resistance in Mycobacterium tuberculosis isolates from South Africa: a genomic analysis. doi:10.1016/S2666-5247(24)00053-3 names it Lancet Microbe 2024
The Role of Efflux Pumps transporter in Multi-drug Resistant Tuberculosis: Mycobacterial memberane protein(MmpL5). doi:10.4103/ijmy.ijmy_37_24 Int J Mycobacteriol 2024
Bactericidal and sterilizing activity of sudapyridine-clofazimine-TB47 combined with linezolid or pyrazinamide in a murine model of tuberculosis. doi:10.1128/aac.00124-24 Antimicrob Agents Chemother 2024
The importance of heteroresistance and efflux pumps in bedaquiline-resistant Mycobacterium tuberculosis isolates from Iran. doi:10.1186/s12941-024-00694-3 Ann Clin Microbiol Antimicrob 2024
Rapid detection of multidrug resistance in tuberculosis using nanopore-based targeted next-generation sequencing: a multicenter, double-blind study. doi:10.3389/fmicb.2024.1349715 Front Microbiol 2024
The exceptions that prove the rule-a historical view of bedaquiline susceptibility. doi:10.1186/s13073-024-01311-w Genome Med 2024
Sub-MIC levels of bedaquiline and clofazimine can select Mycobacterium tuberculosis mutants with increased MIC. doi:10.1128/aac.01275-23 Antimicrob Agents Chemother 2024
Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis. doi:10.1186/s13073-024-01289-5 Genome Med 2024
Identification of genetic determinants of bedaquiline resistance in Mycobacterium tuberculosis in Ural region, Russia. doi:10.1128/spectrum.03749-23 Microbiol Spectr 2024
Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysis. doi:10.1016/S2666-5247(23)00317-8 Lancet Microbe 2024
Genotype-Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis. doi:10.1093/cid/ciad596 Clin Infect Dis 2024
In silico structural and mechanical insights into bedaquiline resistance associated with high-grade non-synonymous mutations in atpE, mmpR5, and pepQ. doi:10.1080/07391102.2023.2259486 names it J Biomol Struct Dyn 2024
Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against Mycobacterium tuberculosis. doi:10.3389/fmed.2023.1304857 Front Med (Lausanne) 2023
Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study. doi:10.1016/S2666-5247(23)00172-6 Lancet Microbe 2023
Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant Mycobacterium Tuberculosis Isolates in Zhejiang, China. doi:10.2147/IDR.S429003 Infect Drug Resist 2023
Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates. doi:10.1093/jac/dkad252 J Antimicrob Chemother 2023
Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678. doi:10.1038/s41598-023-36955-y names it Sci Rep 2023
A Bayesian approach to estimate the probability of resistance to bedaquiline in the presence of a genomic variant. doi:10.1371/journal.pone.0287019 PLoS One 2023
Site-directed mutagenesis of Mycobacterium tuberculosis and functional validation to investigate potential bedaquiline resistance-causing mutations. doi:10.1038/s41598-023-35563-0 Sci Rep 2023
Transmission and resistome of extremely drug-resistant tuberculosis in Beijing, China: A retrospective population-based epidemiological study. doi:10.1016/j.jiph.2023.05.020 J Infect Public Health 2023
Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis. doi:10.1128/aac.01532-22 Antimicrob Agents Chemother 2023
Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: an individual isolate metaanalysis. doi:10.1101/2023.05.04.23289023 medRxiv 2023
Mycobacterium tuberculosis Intra-Host Evolution Among Drug-Resistant Tuberculosis Patients Failing Treatment. doi:10.2147/IDR.S408976 Infect Drug Resist 2023
Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis. doi:10.1016/j.jgar.2023.05.001 J Glob Antimicrob Resist 2023
Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients. doi:10.1016/j.jgar.2023.04.003 J Glob Antimicrob Resist 2023
Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis. doi:10.1016/S2666-5247(23)00002-2 Lancet Microbe 2023
Emergence of Canonical and Noncanonical Genomic Variants following In Vitro Exposure of Clinical Mycobacterium tuberculosis Strains to Bedaquiline or Clofazimine. doi:10.1128/aac.01368-22 Antimicrob Agents Chemother 2023
Circularization of rv0678 for Genotypic Bedaquiline Resistance Testing of Mycobacterium tuberculosis. doi:10.1128/spectrum.04127-22 names it Microbiol Spectr 2023
Investigation of bedaquiline resistance and genetic mutations in multi-drug resistant Mycobacterium tuberculosis clinical isolates in Chongqing, China. doi:10.1186/s12941-023-00568-0 Ann Clin Microbiol Antimicrob 2023
Mutations in Rv0678 Reduce Susceptibility of Mycobacterium tuberculosis to the DprE1 Inhibitor TBA-7371. doi:10.1128/aac.00052-23 names it Antimicrob Agents Chemother 2023
2,4-Disubstituted pyridine derivatives are effective against intracellular and biofilm-forming tubercle bacilli. doi:10.3389/fphar.2022.1004632 Front Pharmacol 2022
Bedaquiline resistant Mycobacterium tuberculosis clinical isolates with and without rv0678 mutations have similar growth patterns under varying BDQ drug pressure. doi:10.1016/j.tube.2022.102266 names it Tuberculosis (Edinb) 2022
Mutation detection and minimum inhibitory concentration determination against linezolid and clofazimine in confirmed XDR-TB clinical isolates. doi:10.1186/s12866-022-02622-x BMC Microbiol 2022
Whole-Genome Sequencing for Resistance Prediction and Transmission Analysis of Mycobacterium tuberculosis Complex Strains from Namibia. doi:10.1128/spectrum.01586-22 Microbiol Spectr 2022
Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis. doi:10.1128/aac.00904-22 names it Antimicrob Agents Chemother 2022
Genome-Wide Study of Drug Resistant Mycobacterium tuberculosis and Its Intra-Host Evolution during Treatment. doi:10.3390/microorganisms10071440 Microorganisms 2022
High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Mycobacterium tuberculosis isolates. doi:10.1080/22221751.2022.2099304 Emerg Microbes Infect 2022
Whole Genome Sequencing Identifies Novel Mutations Associated With Bedaquiline Resistance in Mycobacterium tuberculosis. doi:10.3389/fcimb.2022.807095 Front Cell Infect Microbiol 2022
Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline. doi:10.5588/ijtld.21.0670 names it Int J Tuberc Lung Dis 2022
Identification of Mutations Associated With Macozinone-Resistant in Mycobacterium Tuberculosis. doi:10.1007/s00284-022-02881-x Curr Microbiol 2022
A case of primary multidrug-resistant pulmonary tuberculosis with high minimum inhibitory concentration value for bedaquiline. doi:10.1016/j.jiac.2022.04.028 J Infect Chemother 2022
Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the detection of drug resistance of Mycobacterium tuberculosis in re-treated patients. doi:10.1016/j.tube.2022.102209 Tuberculosis (Edinb) 2022
First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda. doi:10.1186/s13756-022-01101-2 Antimicrob Resist Infect Control 2022
Evolution and spread of a highly drug resistant strain of Mycobacterium tuberculosis in Papua New Guinea. doi:10.1186/s12879-022-07414-2 BMC Infect Dis 2022
atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure. doi:10.3201/eid2805.212517 Emerg Infect Dis 2022
Investigation of Clofazimine Resistance and Genetic Mutations in Drug-Resistant Mycobacterium tuberculosis Isolates. doi:10.3390/jcm11071927 J Clin Med 2022
Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan. doi:10.1186/s12866-022-02475-4 names it BMC Microbiol 2022
Bedaquiline-Resistant Tuberculosis Associated with Rv0678 Mutations. doi:10.1056/NEJMc2103049 names it N Engl J Med 2022
Detection of minor variants in Mycobacterium tuberculosis whole genome sequencing data. doi:10.1093/bib/bbab541 Brief Bioinform 2022
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. doi:10.1016/S1473-3099(21)00470-9 Lancet Infect Dis 2022
Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis. doi:10.1016/s2666-5247(21)00175-0 Lancet Microbe 2021
Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan. doi:10.3389/fmicb.2021.754249 Front Microbiol 2021
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid. doi:10.1038/s41598-021-98862-4 Sci Rep 2021
Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. doi:10.1128/AAC.01412-21 names it Antimicrob Agents Chemother 2021
Role of Epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine Resistance in Mycobacterium tuberculosis Complex. doi:10.1128/AAC.01164-21 Antimicrob Agents Chemother 2021
Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition. doi:10.1186/s13756-021-00995-8 Antimicrob Resist Infect Control 2021
Intragenic Distribution of IS6110 in Clinical Mycobacterium tuberculosis Strains: Bioinformatic Evidence for Gene Disruption Leading to Underdiagnosed Antibiotic Resistance. doi:10.1128/Spectrum.00019-21 Microbiol Spectr 2021
A multi-targeting pre-clinical candidate against drug-resistant tuberculosis. doi:10.1016/j.tube.2021.102104 Tuberculosis (Edinb) 2021
Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China. doi:10.1016/j.jgar.2021.06.007 J Glob Antimicrob Resist 2021
Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China. doi:10.1186/s12879-021-06024-8 BMC Infect Dis 2021
Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey. doi:10.1016/j.jinf.2021.02.004 J Infect 2021
Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. doi:10.1128/AAC.02418-20 names it Antimicrob Agents Chemother 2021
Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. doi:10.1016/j.ijid.2020.10.081 Int J Infect Dis 2021
Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid. doi:10.1093/cid/ciaa1064 Clin Infect Dis 2021
Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China. doi:10.1093/cid/ciaa1002 Clin Infect Dis 2021
Tissue specific diversification, virulence and immune response to Mycobacterium bovis BCG in a patient with an IFN-γ R1 deficiency. doi:10.1080/21505594.2020.1848108 Virulence 2020
Biological Profiling Enables Rapid Mechanistic Classification of Phenotypic Screening Hits and Identification of KatG Activation-Dependent Pyridine Carboxamide Prodrugs With Activity Against Mycobacterium tuberculosis. doi:10.3389/fcimb.2020.582416 Front Cell Infect Microbiol 2020
MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era. doi:10.1186/s13073-020-00793-8 Genome Med 2020
In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates. doi:10.3389/fmicb.2020.559469 Front Microbiol 2020
Resistance against Membrane-Inserting MmpL3 Inhibitor through Upregulation of MmpL5 in Mycobacterium tuberculosis. doi:10.1128/AAC.01100-20 Antimicrob Agents Chemother 2020
Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains. doi:10.1128/JCM.01304-20 J Clin Microbiol 2020
Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. doi:10.1016/S2666-5247(20)30031-8 Lancet Microbe 2020
Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China. doi:10.1016/j.ijid.2020.07.044 Int J Infect Dis 2020
A Multimethod, Multicountry Evaluation of Breakpoints for Bedaquiline Resistance Determination. doi:10.1128/AAC.00479-20 Antimicrob Agents Chemother 2020
Mutation in atpE and Rv0678 genes associated with bedaquline resistance among drug-resistant tuberculosis patients: A pilot study from a high-burden setting in Northern India. doi:10.4103/ijmy.ijmy_30_20 names it Int J Mycobacteriol 2020
Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid. doi:10.3390/antibiotics9030133 Antibiotics (Basel) 2020
Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients. doi:10.1183/13993003.02383-2019 Eur Respir J 2020
Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates. doi:10.1016/j.jinf.2020.01.007 J Infect 2020
Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan. doi:10.1128/AAC.00915-19 Antimicrob Agents Chemother 2019
In Vitro Study of Stepwise Acquisition of rv0678 and atpE Mutations Conferring Bedaquiline Resistance. doi:10.1128/AAC.00292-19 names it Antimicrob Agents Chemother 2019
Multicentre study to establish interpretive criteria for clofazimine drug susceptibility testing. doi:10.5588/ijtld.18.0417 Int J Tuberc Lung Dis 2019
Clofazimine Exposure In Vitro Selects Efflux Pump Mutants and Bedaquiline Resistance. doi:10.1128/AAC.02141-18 Antimicrob Agents Chemother 2019
Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis. doi:10.1016/j.dib.2018.09.057 Data Brief 2018
Whole-genome sequencing reveals genetic signature of bedaquiline resistance in a clinical isolate of Mycobacterium tuberculosis. doi:10.1016/j.jgar.2018.09.006 J Glob Antimicrob Resist 2018
In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants. doi:10.1016/j.mimet.2018.08.011 J Microbiol Methods 2018
Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia. doi:10.1016/j.tube.2018.04.007 Tuberculosis (Edinb) 2018
Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. doi:10.1016/j.ebiom.2018.01.005 EBioMedicine 2018
Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention. doi:10.1093/cid/cix992 Clin Infect Dis 2018
Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis. doi:10.1128/AAC.01692-17 Antimicrob Agents Chemother 2018
In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China. doi:10.1128/AAC.00900-17 Antimicrob Agents Chemother 2017
Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. doi:10.1093/jac/dkx094 J Antimicrob Chemother 2017
Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. doi:10.1128/AAC.00239-17 Antimicrob Agents Chemother 2017
Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. doi:10.1093/jac/dkw502 names it J Antimicrob Chemother 2017
Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease. doi:10.1128/JCM.02087-16 J Clin Microbiol 2017
Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. doi:10.1128/AAC.00753-16 Antimicrob Agents Chemother 2016
Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. doi:10.1093/jac/dkv150 J Antimicrob Chemother 2015
Acquired resistance of Mycobacterium tuberculosis to bedaquiline. doi:10.1371/journal.pone.0102135 PLoS One 2014
Crystal structure of the transcriptional regulator Rv0678 of Mycobacterium tuberculosis. doi:10.1074/jbc.M113.538959 names it J Biol Chem 2014
Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. doi:10.1128/AAC.00037-14 Antimicrob Agents Chemother 2014
Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. doi:10.1016/j.tube.2008.08.003 Tuberculosis (Edinb) 2009

Title+abstract index only: a paper that names this gene solely in its body text, a figure legend or a supplement is invisible here. That is why this list sits beside the curated layer rather than replacing it - Rv0007's characterisation, found by a full-text sweep, returns zero in this one. Absence from this list is not absence from the literature. Source: PubMed E-utilities sweep (esearch + esummary), every alias of the gene searched in conjunction with a mycobacterial context term; ambiguous common-word aliases excluded. phase198, 2026-09-06.

This layer CITES the literature, it does not change the verdict or the function. A gene may be heavily studied (as an antigen, a resistance determinant, a drug target) while its molecular function is settled elsewhere in the fiche. This distinguishes a gene that is dark because nobody has looked from one that is dark despite having been studied. Source: PubMed (whole), MULTI-ALIAS sweep: H37Rv locus tag AND every ortholog identifier (M. bovis Mb…, M. marinum MMAR_…, M. smegmatis MSMEG_…, M. leprae ML…, M. abscessus MAB_…), each hit VERIFIED against the abstract text (word-boundary regex). phase73/phase75, 2026-07-13.

Conditional expression context (iModulons)

Member of 1 independently-modulated gene set(s): Rv2488c (Rv2488c).

iModulon membership (independently-modulated gene sets from a 647-sample RNA-seq compendium): the conditional co-expression context. Co-expression is a regulatory context, NOT a molecular function. Source: iModulonDB / modulome_mtb (Yoo 2022).

Transcriptional start site (informative, coordinates unchanged)

Leaderless transcript (no 5'UTR / Shine-Dalgarno). Primary TSS at position 778988 (+ strand), -7 bp 5'UTR. TSS-derived candidate start codon: 778981 (122 bp from the annotated start) -- candidate only, not applied to this record's coordinates.

Genome-wide 5'-triphosphate-enriched RNA-seq TSS mapping (Cortes et al. 2013): informative context on transcript architecture only. reannotated_start_candidate is the authors' TSS-derived candidate start codon -- reported for information, NEVER applied to this atlas's start_mtbc0/end_mtbc0 coordinates (P19 MTBC0<->H37Rv anchoring). Row re-keyed to this locus by matching its genomic boundary against the H37Rv GFF3 (P49.1 (phase233, 2026-09-15), P49): the original ingestion (P16.23/phase135, 2026-08-17) trusted the source table's own gene-identity column, which was desynchronised from its own numeric columns on 547/651 checkable rows -- see P49 for the full diagnostic. A missing primary_tss here means this gene falls outside the 680-gene re-annotation-candidate subset the source table covers, not an absence of transcription. Leaderless: transcription starts at or within the annotated start codon, so this transcript carries no 5'UTR/Shine-Dalgarno sequence -- relevant context for translation-start calls on short/dark ORFs (P8). Source: Cortes et al. 2013 (Cell Reports), Table S3 (TSS mapping and re-annotation of start codons), 680-gene re-annotation-candidate subset of >4,000 genome-wide TSS -- row re-keyed to this locus by coordinate match (P49).

CRISPRi vulnerability

Vulnerability index 0.59 (95% CI -0.59 to 2.44). A more negative index = more vulnerable to knockdown (better drug-target quality); indicative threshold VI ≤ -6 = highly vulnerable.

Quantitative CRISPRi knockdown, graded (finer than binary Tn-seq essentiality). Source: CRISPRi vulnerability index (Bosch 2021, supplementary Table S2 'mmc3.xlsx', bulk import via Europe PMC -- supersedes the per-gene pebble.rockefeller.edu scrape of phase46_crispri_vulnerability.py).

Caveat on this estimate. Bosch et al. flag this gene's vulnerability estimate as NOT certain, and here that call has a mechanical cause visible in the library itself: every guide targeting this gene is >=21 nt (str_span=0.405 on a 0-1 scale, near the genome floor), and guide repression strength saturates from 21 nt on -- so the library never sampled a partial knockdown for this gene, only the near-maximal repression plateau. The dose-response fit (and this VI) is therefore essentially unconstrained by data, not merely uncertain -- a limitation of the CRISPRi library design for the non-essential class (Bosch et al. 2021), not a defect in this specific measurement. n_guides=6 is descriptive only and does not predict this. Do not cite this VI as a standalone vulnerability claim.

Legacy record & comparison (Mycobrowser) ahead of Mycobrowser

Mycobrowser functionFunction unknown

Mycobrowser classes this locus among conserved hypotheticals; the atlas now assigns a functional handle (curated function (UniProt), COG category). Mycobrowser is no longer maintained, so its EC numbers predate recent nomenclature revisions (e.g. the 2018 EC 7 "translocase" class) — most EC differences are re-numberings of the same enzyme, not conflicts.

Orthologues (reciprocal best hits across mycobacteria)

M. bovis Mb0697 · 99.4% identity
M. marinum MMAR_1007 · 83.0% identity
M. orygis RJtmp_000715 · 99.4% identity

Reciprocal-best-hit orthologues (DIAMOND) against the Mycobrowser reference proteomes. A missing species is informative: e.g. a gene absent from M. leprae was likely lost in its reductive genome evolution. Locus tags link to Mycobrowser.

Curated reference (UniProt)

UniProt I6Y8F7 SwissProt · reviewed · Evidence at protein level
UniProt nameHTH-type transcriptional regulator MmpR5
Curated functionControls the expression level of the Mmps2-MmpL2, MmpS4-MmpL4, and MmpS5-MmpL5 transport systems. Also controls its own expression. Acts by binding directly to the promoter regions.

Functional vocabulary (eggNOG-mapper, orthology transfer)

COG category K Transcription
eggNOG descriptionregulation of RNA biosynthetic process
Orthologous groupCOG1510

Orthology-based transfer (eggNOG 5.0.2, diamond). EC/KO/GO/CAZy are computed annotations, not manual curation; cross-check against the primary literature before treating a specific reaction as established.

Outgroup conservation (beyond the MTBC) Corynebacteriales

M. canettii dN/dS (deep-divergence selection) 0.226 (low power) · 5 consensus substitution(s)
low power (5 canettii-consensus substitution(s)); present in M. canettii but dN/dS not reliable
Limitation: dN/dS mixes fixed canettii-H37Rv divergence with intra-canettii polymorphism, and is not polarised (the per-gene repolarisation is not viable: 79 % of the consensus SPDI lie outside the polarised table).
Genus-wide presence (~53 non-MTBC Mycobacterium) present in 23/53 (43%) · mean identity 49.8% · 1/4 closest MTBAP relatives
present in a subset of the genus (23/53 NTM; in 1 of the 4 closest MTBAP relatives) — partial/intermediate conservation
Phylostratum (deepest detected homolog) MTBC-specific → Mycobacterium → Mycobacteriaceae → Corynebacteriales → Actinomycetia → Bacteria
detected in 2/13 non-Mycobacterium reference genomes (down to Corynebacteriales) · mean identity 32.0%
detected across the order Corynebacteriales (Corynebacterium/Nocardia/Rhodococcus/…) but not in more distant Actinomycetia — a Corynebacteriales-level gene

Two orthogonal outgroup signals. M. canettii (the immediate outgroup) gives a deep-divergence dN/dS (a low value confirms a constrained, real gene; shown as confident only at ≥8 substitutions, else flagged low-power). Genus-wide presence/absence (tblastn vs assembled non-MTBC genomes) places the gene on the ancient-core ↔ MTBC-specific axis: a gene absent even from the closest MTBAP relatives is a candidate MTBC-specific innovation (possible host-adaptation factor, to confirm by synteny). The phylostratum extends that axis outside the genus (tblastn vs 13 reference genomes spanning Mycobacteriaceae → Corynebacteriales → Actinomycetia → outside the phylum): it is the deepest clade in which a homolog is still detected, i.e. a proxy for gene age. Read it with the null model in mind: a shallow (young) stratum can also reflect homology-detection failure for short or fast-evolving ORFs, so it is a descriptive axis, not a proof of novelty.

Essentiality (transposon mutagenesis)

DeJesus 2017 callNE · non-essential
What the call meansnon-essential
TA sites (Himar1) 5 in the ORF — 0 in the essential state, 0 growth-defect, 5 non-essential, 0 growth-advantage. Saturation 1.000, mean read count 315.2. A region of the protein devoid of TA sites is invisible to this assay: nothing can be inferred about it, in either direction.
All 5 sites lie in this ORF alone (no overlapping CDS shares any), so the call is attributable to this gene.
CaveatRead with some caution: only 5 TA (Himar1) sites in the whole ORF (atlas median 13). The DeJesus 2017 call rests on fewer independent observations than for a longer gene. If this gene overlaps a neighbour (see Genomic-neighbour overlap section below), some of these 5 sites may fall inside the neighbour's ORF rather than its own, leaving even fewer truly informative sites than the raw count suggests. (P20.3)

Genome-wide Himar1 transposon essentiality in H37Rv (DeJesus 2017). An essential call (ES/ESD/GD) is strong, independent evidence that a "hypothetical" locus encodes a functional, selectively required gene — orthogonal to intra-species conservation.

Conditional fitness (RB-TnSeq, 95 conditions) stress

ConditionGroupDirectionlog2 fitnesst
Econazole nitrate salt stress mutant enriched (loss advantageous) 2.365 13.82
Clofazimine stress mutant enriched (loss advantageous) 2.116 9.804

Randomly-barcoded transposon screen across 95 carbon/nitrogen sources, pH, stressors and antibiotics (2 condition-specific phenotype(s) for this gene). A conditional fitness phenotype is a context lead, not a proven function, and never changes the verdict here. Note the blind spot: RB-TnSeq cannot measure essential genes. Source: RB-TnSeq 95-condition barcoded transposon screen, Mtb (PLoS Biol 2026, doi:10.1371/journal.pbio.3003529).

Drug resistance (WHO catalogue) bedaquilineclofazimine

bedaquiline226 catalogued resistance-associated variant(s)
clofazimine175 catalogued resistance-associated variant(s)

This gene carries mutations classed Associated with resistance (WHO grade 1–2) in the consolidated catalogue (WHO 2nd ed. 2023 + tb-profiler). Only the R-associated tier is shown; "uncertain" and empirical-only signals are excluded. Test a specific strain or variant with the resistance tester. Research context, not a clinical diagnostic.

Proteomics (mass spectrometry) detected

MS detectiondetected in 15 of 16 independent MS datasets
Integrated abundance477.0 ppm · rank 423/3519 (88.0th percentile)

Detection by mass spectrometry is direct, experimental evidence that the protein product exists — orthogonal to sequence conservation and to Tn-seq essentiality, and especially decisive for a "hypothetical" locus. Read the dataset count as abundance, not as replication. Measured across this atlas (3,491 detected proteins), the number of datasets a protein appears in tracks its abundance almost monotonically: median 1.2 ppm at 1 dataset of 16, 27 ppm at 10, 392 ppm at 15, 1,325 ppm at 16 — three orders of magnitude. A high count therefore says the protein is abundant more than it says several independent experiments confirmed it. What the count does establish, at any value, is that the product exists.

Predicted localisation (DeepTMHMM + lipobox) no export signal, no TM helix

Predictionno signal peptide, no TM helix (DeepTMHMM class GLOB)
DeepTMHMM classGLOB

A verified absence of signals, which is not a compartment. No Sec/Tat signal peptide, no transmembrane helix and no lipobox were found on this sequence. The predictor reports topology and export signals; it does not measure where the protein ends up, so this page draws no cytoplasmic conclusion from it. In M. tuberculosis that reservation is not theoretical: the 12 Esx paralogues of this atlas — EsxA/ESAT-6 and EsxB/CFP-10 among them, the best-established secreted proteins of the species — carry this very call, because substrates of the type VII (ESX) secretion system leave no recognisable signal. « Secreted » and « no signal peptide » are true together here.

Transmembrane topology and signal peptide from DeepTMHMM (deep-learning reference predictor); lipoproteins from a (myco)bacterial lipobox motif. A sequence-based prediction of subcellular context.

Physico-chemical properties (computed, ProtParam)

Length165 aa
Molecular weight18.4 kDa
Theoretical pI4.95
GRAVY-0.36 (hydrophilic)
Aliphatic index82.3
Aromaticity0.067
Instability index56.8 (unstable)

Computed from the ancestral MTBC0 sequence with the ExPASy ProtParam method (Biopython). Descriptive biophysical context: a positive GRAVY flags a hydrophobic (often membrane) protein, a high instability index (>40) predicts a short in-vitro half-life, an extreme pI hints at compartment or binding partner.

Domains (Pfam, hmmscan --cut_ga)

PfamAccessioni-EvalueResiduesDescription
HTH_MmpR5PF27059.1 7.0e-1598–159 MmpR5-like MarR family transcriptional regulator

3D structure (interactive — Mol*/pdbe-molstar)

Experimental structure 4nb5 (PDBe), the strongest available structural evidence for this gene. Drag to rotate, scroll to zoom; hetero-groups (ligands, ions, waters hidden by default) shown as sticks.

Experimental structures (Protein Data Bank) 1 solved

PDBMethodResolutionCoverage
4nb5 X-ray diffraction 1.641 Å 99%

Experimentally solved structures mapped from the UniProt accession via PDBe/SIFTS (1 total; up to 8 shown, ranked by sequence coverage then resolution). An experimental structure is direct proof of the folded product and the strongest structural evidence — superseding the predicted ESMFold/AlphaFold models below for any covered region.

Structural search (AlphaFold DB model, Foldseek vs PDB — genome-wide) pLDDT 92.0

PDB hitprobTM (aln)TM (query)TM (target)Seq. id.Cov. q / tE-valueDescription
4nb5-assembly1_C 1.00 0.98 0.87 0.98 100% 88% / 99% 3.4e-24 sig 4nb5-assembly1_C Crystal Structure of a transcriptional regulator
1ku9-assembly1_B 1.00 0.69 0.62 0.67 13% 84% / 95% 1.0e-07 sig 1ku9-assembly1_B X-ray Structure of a Methanococcus jannaschii DNA-Binding Protein: Implications for Antibiotic Resistance in Staphylococcus aureus
5jbr-assembly1_B 1.00 0.65 0.56 0.64 22% 84% / 95% 2.4e-07 sig 5jbr-assembly1_B Crystal structure of uncharacterized protein Bcav_2135 from Beutenbergia cavernae
8ylg-assembly1_B 1.00 0.52 0.40 0.42 22% 74% / 74% 4.5e-04 sig 8ylg-assembly1_B Crystal structure of Burkholderia thailandensis MftR in complex with operator DNA
4ld5-assembly3_G 1.00 0.49 0.41 0.47 17% 79% / 90% 3.8e-04 sig 4ld5-assembly3_G Crystal structure of MepR Q18P mutant from multidrug resistant S. aureus clinical isolate

Foldseek search of the AlphaFold DB model (mean pLDDT 92.0, gated at 70) against the PDB — a genome-wide extension of the ESMFold dark-gene search that also covers proteins beyond the single-sequence length limit. Confident structural neighbours (E < 0.01) shown.

Genomic context (neighbours & predicted operon)

Upstream (5' on genome)mmpS5 (- strand, 84 bp gap)
Downstream (3' on genome)Rv0679c (- strand, 55 bp gap)

Neighbours from the H37Rv annotation (+ strand). The operon is predicted by co-directional intergenic distance (same strand, gaps ≤50 bp) — a transcription-unit hypothesis, not a mapped TSS. For a "hypothetical", co-transcription with a characterised operon is a concrete functional lead (complements the STRING neighborhood channel below).

Published operon evidence (two independent sources)

Roback 2007 (logistic regression: distance + expression correlation, 474 microarrays) no multi-gene operon predicted (singleton)
REMap 2016 (RNA-seq coverage continuity, CDC1551, tag MT0706.1) expressed, no multi-gene operon (exponential phase, coverage 72.69)
expressed, no multi-gene operon (stationary phase, coverage 365.36) — agrees with the distance heuristic above

Two independent published operon maps, cited alongside the distance heuristic above: an association corroborating or contradicting the heuristic, never proof of shared function. REMap's RNA-seq coverage continuity is the most direct of the three signals; Roback's logistic regression and the intergenic-distance heuristic are statistical proxies.

Transcriptional regulation (signed TRN: ChIP-seq + TFOE) transcription factor

Regulated by (1 TF) mmpR5 (activates)
Regulonthis transcription factor regulates 212 target gene(s)

Regulatory edges from the ISB signed transcriptional regulatory network (TF ChIP-seq binding, Minch 2015 + TF-overexpression response, Rustad 2014). An edge is regulatory evidence (binding and/or expression change), not necessarily direct. For a "hypothetical", membership in a known regulon (e.g. DosR dormancy, PhoP virulence) is a physiological-context lead, not a function.

Condition: Condition-blind by construction. These edges come from transcription-factor OVEREXPRESSION in a single laboratory condition, so a listed regulator is not a claim that it governs this gene in every circumstance. Measured counter-examples exist within this atlas (see Rv2516c, where the DosR regulon collapses under moxifloxacin while the gene itself rises). Read a regulator as 'capable of shifting this gene', and look for the condition before building a hypothesis on it.

Functional interaction network (STRING v12, guilt-by-association)

Explore full network →

Node colour = verdict, dashed = still uncharacterised; edge colour = evidence (green experimental, orange genomic-context, grey co-expression), width ∝ score. Click a partner to open its page; "Explore full network" to walk the graph.

Closest characterised functional partner: mmpL5 (transmembrane transport protein MmpL5), high confidence (score 915, all STRING channels except text-mining; the partner is chosen on its genomic-context evidence).

Showing the 15 strongest of this gene's 30 partners at medium confidence (9 at high confidence). The table is an extract, not a neighbourhood: across the proteome the real median degree is 34 while the served median is 15, so no hub, degree distribution or centrality may be read on this table. None of the 30 partners rests on an interaction measured in M. tuberculosis itself.

PartnerProductScoreNo text-miningChannels (≥400)
Rv0676c mmpL5 transmembrane transport protein MmpL5 989 915 ctx neighborhood:571 coexpression:810 textmining:883
Rv0677c mmpS5 membrane protein MmpS5 974 814 ctx neighborhood:601 coexpression:553 textmining:870
Rv3160c TetR family transcriptional regulator 799 799 coexpression:799
Rv3066 DeoR family transcriptional regulator 812 773 coexpression:739
Rv1152 transcriptional regulator 580 580 coexpression:580
Rv0792c transcriptional regulator 474 474 coexpression:474
Rv1733c transmembrane protein 426 426 ctx cooccurence:423
Rv1404 transcriptional regulator 474 326
Rv1455 hypothetical protein 416 234
Rv3855 ethR HTH-type transcriptional repressor EthR 442 212
Rv1453 transcriptional activator protein 533 85 textmining:511
Rv1049 transcriptional repressor 811 80 textmining:803
Rv0880 HTH-type transcriptional regulator 559 65 textmining:548
Rv2043c pncA pyrazinamidase/nicotinamidase PncA 572 64 textmining:562
Rv1173 fbiC FO synthase 663 58 textmining:657

STRING combines evidence channels (neighborhood, fusion, cooccurrence, coexpression, experimental, database, text-mining) into a 0–1000 score. The ctx badge marks edges carried by the genomic-context channels (conserved neighborhood, fusion, phylogenetic co-occurrence), which are independent of orthology and structure and the strongest signal for an unknown gene. The no text-mining column recomputes the score from data alone, so a link that does not depend on the literature is visible. Association is a function hypothesis, not proof: corroborate with the operon context and the primary literature before assigning a function.

Where the experimental evidence comes from, and why it matters here. STRING's experimental channel fuses interactions measured in M. tuberculosis with interactions measured in another organism and transferred to this pair by orthology. The two are not equivalent for this atlas, whose standing rule is that better studied elsewhere is not a function established in M. tuberculosis. Measured on the served network: of the 38 229 partner pairs shown across the atlas, 13 483 partner rows carry a non-zero experimental channel, and only 106 pairs rest on an interaction measured in M. tuberculosis itself — 0.3 % of the network. Those 106 are long-established complexes (ESX-1/ESAT-6, RNA polymerase with CarD and RbpA, the Pup–Mpa proteasome, gyrase, Emb, GarA with PknB and PknG, the Rel modules); no still-uncharacterised gene is among them. The reason is not a gap in this atlas but in the literature: there is almost no experimental interactome of this bacterium, IntAct holding 134 curated protein pairs for a ~4 000-gene proteome. A exp (transferred) badge is therefore a lead, never a measurement, and an absence of badge is not evidence that the pair does not interact.

Evidence

  • Legacy H37Rv annotation: hypothetical protein
  • MTBC0 PGAP product: siderophore transport transcriptional regulator MmpR5
  • Pfam (hmmscan --cut_ga): HTH_MmpR5 PF27059.1 (E=7e-15)
  • (auto-curated by rules from PGAP + Pfam + Foldseek; not hand-reviewed)

Sources

  • Ancestral sequence & coordinates: Harrison LB et al. (2024), An imputed ancestral reference genome for the MTBC, doi:10.1101/2023.09.07.556366
  • Product annotation: NCBI PGAP on MTBC0; legacy from H37Rv NC_000962.3 (RefSeq NP_215192.1)
  • Domains: Pfam-A via hmmscan --cut_ga — HTH_MmpR5 (PF27059.1)
  • Sequence-level signal: ESM Atlas (EvolutionaryScale × BioHub) — exploratory
  • Controlled vocabulary: eggNOG-mapper 2.1.12 (Cantalapiedra et al. 2021, doi:10.1093/molbev/msab293), eggNOG 5.0 DB (Huerta-Cepas et al. 2019) — OG COG1510
  • Curated reference: UniProt I6Y8F7 (SwissProt, reviewed; Evidence at protein level)
  • Genome-wide structure: AlphaFold DB model (Jumper et al. 2021, doi:10.1038/s41586-021-03819-2; Varadi et al. 2024, doi:10.1093/nar/gkad1011) searched vs PDB with Foldseek (mean pLDDT 92.0)
  • Interaction network: STRING v12.0 (Szklarczyk et al. 2023, doi:10.1093/nar/gkac1000), taxon 83332, CC-BY 4.0 — 30 functional partner(s); context anchor mmpL5
  • Essentiality: genome-wide transposon mutagenesis in H37Rv — DeJesus et al. 2017 (mBio, doi:10.1128/mBio.02133-16, CC BY)
  • Proteomics: integrated mass-spectrometry abundance from PaxDb 5.0 (Huang et al. 2023, doi:10.1016/j.mcpro.2023.100640), taxon 83332 — weighted average of 16 datasets, incl. Schubert et al. 2013 (doi:10.1016/j.chom.2013.04.008) and Albrethsen et al. 2013 (doi:10.1074/mcp.M112.018846)
  • Functional category: TubercuList scheme (Cole et al. 1998, doi:10.1038/31159), via Mycobrowser (Kapopoulou et al. 2011, doi:10.1016/j.tube.2010.09.006)
  • Orthologues: reciprocal best hits (DIAMOND, Buchfink et al. 2021, doi:10.1038/s41592-021-01101-x) against Mycobrowser release 5 reference proteomes
  • Experimental structures: PDBe/SIFTS UniProt→PDB mapping (Dana et al. 2019, doi:10.1093/nar/gky1114)
  • Genomic context / operon: H37Rv annotation; operon predicted by co-directional intergenic distance (Salgado et al. 2000, doi:10.1073/pnas.030539397)
  • Transcriptional regulation: ISB signed TRN — TF ChIP-seq (Minch et al. 2015, doi:10.1038/ncomms6829) + TF overexpression (Rustad et al. 2014, doi:10.1186/gb-2014-15-11-502)
  • Drug resistance: consolidated catalogue, WHO 2nd ed. 2023 (9789240082410) + tb-profiler; only the resistance-associated tier (grade 1–2) is surfaced
  • Physico-chemical properties: ExPASy ProtParam method via Biopython (Gasteiger et al. 2005), computed from the MTBC0 sequence
  • Predicted localisation: DeepTMHMM (Hallgren et al. 2022, doi:10.1101/2022.04.08.487609) for transmembrane topology and signal peptide
  • Primary literature: none located yet; annotation rests on the domain/homology sources above.

Ancestral MTBC0 protein sequence

>mtbc0_000717|Rv0678|mmpR5
MSVNDGVDQMGAEPDIMEFVEQMGGYFESRSLTRLAGRLLGWLLVCDPERQSSEELATALAASSGGISTNARMLIQFGFIERLAVAGDRRTYFRLRPNAFAAGERERIRAMAELQDLADVGLRALGDAPPQRSRRLREMRDLLAYMENVVSDALGRYSQRTGEDD